Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Withdrawn 1Unknown 1Terminated 1Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 19Myeloid 8Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Medulloblastoma 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 19Magnetic Resonance Spectroscopy 16Radiosurgery 12Bevacizumab 12Radiotherapy 10Radiation 8pembrolizumab 6Specimen Handling 6Methotrexate 6Surgical Procedures, Operative 5Topotecan 4TIC10 compound 4Isotretinoin 4Carmustine 4Carboplatin 4abemaciclib 3Trastuzumab 3Thiotepa 3Standard of Care 3Nivolumab 3Magnetic Resonance Imaging 3Lomustine 3Irinotecan 3Erlotinib Hydrochloride 3Drug Therapy 3Dexamethasone 3vandetanib 2thymoglobulin 2temsirolimus 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Azacitidine × CNS × Clear all
NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

The University of Texas Health Science Center, Houston

Phase 1 Withdrawn
CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡